Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
42,884,873
-
Share change
-
+1,998,225
-
Total reported value
-
$3,253,105,466
-
Put/Call ratio
-
100%
-
Price per share
-
$75.78
-
Number of holders
-
425
-
Value change
-
+$73,035,179
-
Number of buys
-
195
-
Number of sells
-
218
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2021
As of 31 Dec 2021 CRISPR Therapeutics AG - Common Stock (CRSP) had 425 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 42,884,873 shares of stock of the company.
Largest 10 holders included ARK Investment Management LLC, Nikko Asset Management Americas, Inc., Capital International Investors, NEA Management Company, LLC, LOOMIS SAYLES & CO L P, BlackRock Inc., CREDIT SUISSE AG/, PRICE T ROWE ASSOCIATES INC /MD/, EcoR1 Capital, LLC, and Bellevue Group AG.
This table shows 425 institutional shareholders of the security as of 31 Dec 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.